We’ve met the enrollment target in our pivotal Phase 3 PREVAIL CVOT and, driven by strong interest globally, expect to randomize more than 9,000 patients with a history of ASCVD. bit.ly/3TTqpAs
2
7
41
3K
0
Download Image
@NewAmsPharma @JohnKastelein @mdavidsonmd It does reduce the Lp(a) too correct?